Tracers / [90Y]Y-FAPI-46
[90Y]Y-FAPI-46
Also written as [90Y]Y-FAPI-46; [Y-90]Y-FAPI-46
- Radionuclide
- Y-90 t½ 3843 min
- Modality
- Therapy
- Production route
- —
- Stage
- early-stage clinical evidence / investigational
- Syntheses indexed
- 6
What it is
- Compound class
- FAP inhibitor (FAPI) radiotracer
- Target / mechanism
- Fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts PMID 41599688
- Clinical application
- Radioligand therapy targeting FAP-expressing tumours (e.g. solitary fibrous tumours) using 90Y-FAPI-46 PMID 42495195
- Theranostic pair
- <a href="/tracers/ga68-fapi46/">ga68-fapi46</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 42495195 2026 Am J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 41886137 2026 Curr Treat Options Oncol |
| — | — | — | — | — | — | 41599688 2026 Pharmaceuticals (Basel) |
| Manual synthesis | — | — | — | — | — | 39207485 2024 Eur J Nucl Med Mol Imaging The patient received two cycles with 3.7 GBq and 7.4 GBq [90Y]Y-FAPI-46 six weeks apart. |
| — | — | — | 56 ± 5% | >99% | FAPI-46 | 35533534 2022 Nucl Med Biol the cassette based synthesis module Trasis EASYONE — a radiochemical yield of 88 ± 7% and 56 ± 5% |
| — | — | — | — | — | — | 41714122 2026 J Nucl Med |
Need this precursor?We can point you to suppliers for [90Y]Y-FAPI-46, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [90Y]Y-FAPI-46.
Get in touchNotes
Added from reverse module search (stage 6); 4 article(s) with Y-90. Stage set/updated at stage 23 from PMID 41599688: 'Therapeutic evidence shows encouraging tumour retention and safety profiles for agents such as [177Lu]Lu-FAP-2286 and [90Y]Y-FAPI-46, while α-emitting radiotracers (e.g., [225Ac]Ac-FAPI-04) demonstrate potent antitumor effects in preclinical models.'. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review.